利用细胞免疫疗法治疗EBV相关的恶性瘤:目前的进展和未来的方向
Yang Gao1, Di Wang1, Chunrui Li1
1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Journal of cellular and molecular medicine
|May 22, 2025
概括
针对爱斯坦-巴尔病毒 (EBV) 的创新细胞免疫疗法对与EBV相关的恶性瘤有希望. 这些疗法为传统治疗提供了更安全,更有效的替代方案,目前正在进行的研究重点是优化它们的使用.
科学领域:
- 瘤学和免疫学
- 细胞疗法细胞疗法
- 病毒性恶性瘤
背景情况:
- 与EBV相关的恶性瘤的标准治疗在复发/耐药病例中缺乏有效性.
- 对于新的治疗策略有着至关重要的需求.
- 免疫疗法,特别是基于T细胞的方法,正在成为一个有前途的替代方案.
研究的目的:
- 审查埃普斯坦-巴尔病毒 (EBV) 导向的细胞疗法背后的逻辑.
- 概述这些疗法的当前临床应用.
- 讨论优化针对EBV的细胞治疗的局限性和未来机会.
主要方法:
- 对EBV特异性细胞毒性T淋巴细胞和树突细胞疫苗的临床前和临床数据的审查.
- 对工程T细胞疗法的分析,包括针对EBV抗原 (LMP1,gp350) 的T细胞受体 (TCR) 和仿制抗原受体 (CAR) 方法.
- 细胞免疫疗法与传统化疗和放射疗法的比较.
主要成果:
- 针对EBV的特异性T细胞疗法显示出治疗和预防EBV相关恶性瘤的潜力.
- 针对EBV抗原的工程T细胞疗法 (TCR,CAR) 正在临床开发中取得进展.
- 与传统疗法相比,细胞免疫疗法具有良好的安全性,在体内强大的T细胞扩张和强大的抗瘤作用.
结论:
- 针对EBV的细胞疗法比传统治疗EBV相关癌症的治疗方法有前途.
- 为了最大限度地提高疗效和可访问性,治疗方案的进一步完善至关重要.
- 目前正在进行的研究旨在克服当前的局限性,并优化这些创新的免疫治疗策略.
相关概念视频
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457